OncoSil Medical Ltd · ASX:OSL

OncoSil Medical — Shareholder Meeting (November 2026)

16 slides from OncoSil Medical's shareholder meeting presentation, Nov 18, 2026

  1. Slide 1: Chairman's Address to 2026 Annual General Meeting

    ASX Announcement 18 November 2026 For personal use only Chairman’s Address to 2026 Annual General Meeting Sydney, Australia – 18 November 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresect

  2. Slide 2: Chairman's Address (continued)

    expanding our label to better align with current standards of care. PANCOSIL demonstrated that percutaneous delivery is both safe and feasible, while interim data from the For personal use only OSPREY registry showed median overall survival of 20.6 and 22.0 months in first-line patients. The Company

  3. Slide 3: Chairman's Address close and About OncoSil Medical

    On behalf of the Board, I would like to thank our shareholders for their continued support and confidence, our employees for their dedication and commitment, our clinicians and investigators for advancing the clinical evidence supporting our technology, and our partners for their collaboration throu

  4. Slide 4: Commercial Inflection: Capitalising on global regulatory approvals

    rsonal use only AGM Presentation Commercial Inflection: Capitalising on global regulatory approvals and high-margin scalability OncoSil Medical Limited (ASX:OSL) 18 November 2026

  5. Slide 5: Disclaimer

    Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil, OSL or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the inf

  6. Slide 6: Corporate Summary

    Corporate Summary Focus Directors / Management A medical device company focused on localised treatments Dr Thomas Duthy Non-Executive Chairman for patients with unresectable locally advanced pancreatic rsonal use only cancer (LAPC) and distal cholangiocarcinoma (dCCA) Nigel Lange CEO & Managing Dire

  7. Slide 7: Unlocking scalable execution in endoscopy and interventional oncology

    Unlocking scalable execution in endoscopy and interventional oncology Targeting unresectable Locally Advanced Pancreatic Cancer (uLAPC) and Distal Cholangiocarcinoma (dCCA) rsonal use only OncoSil Medical (ASX:OSL) is an advanced, early commercial-stage global medical technology innovator that has t

  8. Slide 8: Unlocking a A$6.4 billion global market

    Unlocking a A$6.4 billion1 global market From regulatory milestones to commercial scalability Key strategic pillars: rsonal use only OncoSil Medical has successfully advanced past the high-risk R&D The transition point and clinical trial phase into a fully approved, commercially executing medical te

  9. Slide 9: The US strategy: High-margin asset execution

    The US strategy: High-margin asset execution Maximising value via the US FDA Humanitarian Device Exemption (HDE) pathway US FDA HDE approval grants immediate marketing authorisation for distal rsonal use only cholangiocarcinoma (dCCA) bypassing years of traditional clinical trials to unlock a The st

  10. Slide 10: De-risked pathway to global execution

    De-risked pathway to global execution Our message to Shareholders rsonal use only OncoSil Medical is no longer is noa longer story about a story clinical abouttrials clinical andtrials regulatory and regulatory checkboxes—that checkboxes risk - that is behind risk isus. behind Withus. globalglobal W

  11. Slide 11: Established funding channels & expanding the clinical label

    Established funding channels & expanding the clinical label Driving commercial adoption via peer-reviewed evidence in uLAPC German G-BA Approval: Formally approved by Federal Joint Committee (Gemeinsammer rsonal use only Bundesausschuss), this legal framework establishes a Coverage with Evidence Dev

  12. Slide 12: A consistent survival signal

    A consistent survival signal Exceptional survival profiles validated across multiple tiers of clinical evidence The OncoSil device demonstrates highly consistent performance metrics across all rsonal use only Clinical performance trial frameworks, geographies and delivery methodologies: Randomised c

  13. Slide 13: Asset scalability & core value drivers

    Asset scalability & core value drivers Premium recurring economics (All figures in A$) OncoSil Medical (ASX:OSL) presents a highly efficient, high-margin commercial investment case with a market rsonal use only capitalisation of A$25.2M. Backed by a 44% YoY increase in FY26¹ reported product revenue

  14. Slide 14: A Natural Fit for Interventional Oncology, with Near-Term Catalysts

    A Natural Fit for Interventional Oncology, with Near-Term Catalysts CT-guided Percutaneous Delivery Near-Term Catalysts rsonal use only Broader Physician Access US dCCA launch - 1H CY27 Expands the treating base to include Interventional Radiologists Up to five centres within a 30-patient FDA post-a

  15. Slide 15: The 12-month shareholder catalyst runway

    The 12-month shareholder catalyst runway Execution-driven milestones driving top-line revenue growth Key strategic catalysts: rsonal use only G-BA Trial European Label US Site Activation & Australian Commercial Commencement Expansion regulatory Revenue (1H CY27) Launch (1H CY27) (1H CY27) submission

  16. Slide 16: For more information, please contact

    rsonal use only Targeted approach • Positive impact For more information, please contact: CEO & Managing Director Nigel Lange nigel.lange@oncosil.com OncoSil Medical Limited (ASX:OSL) Level 5, 7 Eden Park Drive Macquarie Park, NSW, 2113 +61 2 8935 9629 www.investors.oncosil.com 13

OncoSil Medical — Shareholder Meeting (November 2026) on 6ix